LeMaitre Vascular Inc. (NASDAQ:LMAT) declared a quarterly dividend on Thursday, October 27th. Investors of record on Monday, November 21st will be given a dividend of 0.045 per share on Monday, December 5th. This represents a $0.18 annualized dividend and a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, November 17th.

LeMaitre Vascular (NASDAQ:LMAT) opened at 23.00 on Wednesday. The company’s 50 day moving average is $20.56 and its 200 day moving average is $17.42. The firm has a market cap of $427.41 million, a P/E ratio of 41.89 and a beta of 0.58. LeMaitre Vascular has a 52-week low of $12.03 and a 52-week high of $24.36.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, October 26th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.02. LeMaitre Vascular had a net margin of 12.19% and a return on equity of 12.83%. The company had revenue of $19 million for the quarter, compared to the consensus estimate of $22.20 million. During the same period last year, the firm posted $0.11 EPS. LeMaitre Vascular’s revenue for the quarter was up 22.1% on a year-over-year basis. Equities research analysts forecast that LeMaitre Vascular will post $0.58 EPS for the current fiscal year.

Dividend History for LeMaitre Vascular (NASDAQ:LMAT)

Several brokerages have recently weighed in on LMAT. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday. Sidoti downgraded shares of LeMaitre Vascular from a “buy” rating to a “neutral” rating and set a $23.00 target price on the stock. in a report on Thursday, September 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $21.00 target price on shares of LeMaitre Vascular in a report on Tuesday, September 6th. Barrington Research lifted their target price on shares of LeMaitre Vascular from $18.50 to $20.00 and gave the company an “outperform” rating in a report on Thursday, July 28th. Finally, Brean Capital lifted their target price on shares of LeMaitre Vascular from $17.50 to $20.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $20.50.

In other LeMaitre Vascular news, insider Peter R. Gebauer sold 3,431 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $18.20, for a total transaction of $62,444.20. Following the completion of the transaction, the insider now owns 31,283 shares in the company, valued at $569,350.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Cornelia W. Lemaitre sold 22,500 shares of LeMaitre Vascular stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $17.36, for a total transaction of $390,600.00. Following the transaction, the director now owns 188,858 shares of the company’s stock, valued at approximately $3,278,574.88. The disclosure for this sale can be found here. 28.90% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of LeMaitre Vascular by 11.2% in the second quarter. Vanguard Group Inc. now owns 583,928 shares of the company’s stock worth $8,333,000 after buying an additional 58,998 shares during the last quarter. Columbia Wanger Asset Management LLC boosted its position in shares of LeMaitre Vascular by 887.9% in the second quarter. Columbia Wanger Asset Management LLC now owns 559,839 shares of the company’s stock worth $7,989,000 after buying an additional 503,169 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of LeMaitre Vascular by 71.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 444,008 shares of the company’s stock worth $8,809,000 after buying an additional 184,865 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of LeMaitre Vascular by 8.1% in the third quarter. BlackRock Fund Advisors now owns 378,580 shares of the company’s stock worth $7,511,000 after buying an additional 28,354 shares during the last quarter. Finally, Panagora Asset Management Inc. boosted its position in shares of LeMaitre Vascular by 1.1% in the second quarter. Panagora Asset Management Inc. now owns 259,851 shares of the company’s stock worth $3,708,000 after buying an additional 2,783 shares during the last quarter. Institutional investors own 60.90% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

5 Day Chart for NASDAQ:LMAT

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.